Found Industries and ARES Strategic Mining Sign MOU to Advance Domestic Gallium, Germanium and Fluorspar Recovery from Utah's Lost Sheep Mine

Found Industries and ARES Strategic Mining signed an MOU to evaluate recovery of gallium, germanium and other strategic critical materials from feedstocks tied to the Lost Sheep Mine in Utah. The initiative centers on resin-free electrochemical Direct Feedstock Extraction technology at the only currently permitted fluorspar mine in the United States. The announcement is strategically positive for domestic critical-minerals supply, but it is still an early-stage evaluation rather than a binding production deal.

Analysis

This is less a headline about one junior miner and more a signal that the US is trying to bolt a domestic critical-minerals recovery layer onto an already strategically constrained feedstock chain. If the extraction process proves viable, the economic value is not in immediate ounces or pounds but in converting low-value byproduct streams into policy-sensitive outputs with far better margin density and optionality. That creates a call option on whoever controls the feedstock, but the real beneficiaries are likely the process-tech provider and any downstream manufacturers exposed to Chinese export controls on gallium/germanium.

The second-order effect is competitive pressure on non-US processors and toll refiners: even small domestic recoveries can alter procurement behavior for defense, RF semiconductor, and specialty alloy buyers who care more about supply assurance than spot price. In a tight market, a credible US source reduces the probability that end users must carry 6-12 months of inventory, which can flatten forward curves and compress margins for import-dependent intermediaries. For ARSMF, the market may be too focused on “new mine upside” rather than the more realistic outcome: an expensive pilot that becomes valuable only if it unlocks a government-backed offtake or grants stack.

The catalyst path is slow. Over the next 30-90 days, this is mostly an execution and financing story; over 6-18 months, the key is whether assay, recovery rates, and impurity handling can meet commercial thresholds at scale. The main reversal risk is that DFX economics look compelling in a press release but fail once capex, reagents, power, and downstream purification are fully loaded — especially if recoveries are subscale or if the feedstock variability is too high.

Consensus may be underestimating how much this kind of project can benefit from industrial policy even if it never becomes a standalone economic winner. If the technology demonstrates any repeatable recovery profile, it could attract non-dilutive funding and strategic partnership value far exceeding near-term operating cash flow. The contrarian view, however, is that the stock can overshoot on “critical minerals” scarcity narrative before any real de-risking, making the setup more about milestone-trading than fundamental re-rating.

Key Decisions for Investors

• Speculative long ARSMF only as a catalyst trade into proof-of-concept milestones; size small and treat as a 6-12 month binary execution bet. Upside can be large if government/strategic partners validate the process, but downside remains high if recoveries fail to scale.
• Consider a pair trade: long ARSMF vs. short a basket of import-dependent specialty-material processors exposed to gallium/germanium supply risk. The long leg benefits if domestic recovery becomes credible; the short leg cushions commodity-story multiple compression.
• Add a watchlist position in process-technology beneficiaries tied to critical minerals recovery and separation, with a 3-9 month horizon. If this model works, the value accrues to the extractor tech stack faster than to the mine owner.
• Do not chase after the first headline pop; wait for disclosure on recovery rates, impurity specs, and capex intensity before taking size. If pilot economics are published and meet industrial thresholds, then re-enter on confirmation rather than anticipation.
• If ARSMF rallies sharply on narrative alone, sell call spreads or fade strength on any move that prices in full commercialization within 12 months. The market is likely to over-discount policy support before technical risk is resolved.